References
- Crispe IN . The liver as a lymphoid organ. Annu. Rev. Immunol.27 , 147–163 (2009).
- Gao B , JeongWI, TianZ. Liver: an organ with predominant innate immunity. Hepatology47(2) , 729–736 (2008).
- Swain MG . Natural killer T cells within the liver: conductors of the hepatic immune orchestra. Dig. Dis.28(1) , 7–13 (2010).
- Wisse E , LuoD, VermijlenD, KanellopoulouC, De Zanger R, Braet F. On the function of pit cells, the liver-specific natural killer cells. Semin. Liver Dis.17(4) , 265–286 (1997).
- O‘Connell PJ , MorelliAE, LogarAJ, ThomsonAW. Phenotypic and functional characterization of mouse hepatic CD8 α + lymphoid-related dendritic cells. J. Immunol.165(2) , 795–803 (2000).
- Starzl TE , DemetrisAJ, TruccoM et al. Systemic chimerism in human female recipients of male livers. Lancet 340(8824) , 876–877 (1992).
- Bishop GA , IerinoFL, SharlandAF et al. Approaching the promise of operational tolerance in clinical transplantation. Transplantation 91(10) , 1065–1074 (2011).
- Stauffer JK , ScarzelloAJ, JiangQ, WiltroutRH. Chronic inflammation, immune escape and oncogenesis in the liver: a unique neighborhood for novel intersections. Hepatology doi:10.1002/hep.25674 (2012) (Epub ahead of print).
- Matar P , AlanizL, RozadosV et al. Immunotherapy for liver tumors: present status and future prospects. J. Biomed. Sci. 16 , 30 (2009).
- Mazzolini G , PrietoJ, MeleroI. Gene therapy of cancer with interleukin-12. Curr. Pharm. Des.9(24) , 1981–1991 (2003).
- Colombo MP , TrinchieriG. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev.13(2) , 155–168 (2002).
- Leonard JP , ShermanML, FisherGL et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 90(7) , 2541–2548 (1997).
- Berraondo P , PrietoJ, Gonzalez-AseguinolazaG. Advances in interleukin-12 gene therapy for acquired liver diseases. Curr. Gene Ther.9(2) , 62–71 (2009).
- Sangro B , MazzoliniG, RuizJ et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J. Clin. Oncol. 22(8) , 1389–1397 (2004).
- Reboredo M , ZabalaM, MauleonI et al. Interleukin-12 inhibits liver-specific drug-inducible systems in vivo. Gene Ther. 15(4) , 277–288 (2008).
- Zabala M , LasarteJJ, PerretC et al. Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J. Hepatol. 47(6) , 807–815 (2007).
- Waldmann TA , LugliE, RoedererM et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 117(18) , 4787–4795 (2011).
- Steel JC , WaldmannTA, MorrisJC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci.33(1) , 35–41 (2012).
- Melero I , Hervas-StubbsS, GlennieM, PardollDM, ChenL. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer7(2) , 95–106 (2007).
- Peggs KS , QuezadaSA, AllisonJP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin. Exp. Immunol.157(1) , 9–19 (2009).
- Hodi FS , O‘DaySJ, McDermottDF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8) , 711–723 (2010).
- Robert C , ThomasL, BondarenkoI et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26) , 2517–2526 (2011).
- Topalian SL , HodiFS, BrahmerJR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26) , 2443–2454 (2012).
- Brahmer JR , TykodiSS, ChowLQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26) , 2455–2465 (2012).
- Saenger YM , WolchokJD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun.8 , 1 (2008).
- Ribas A . Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin. Oncol.37(5) , 450–454 (2010).
- Ascierto PA , SimeoneE, SznolM, FuYX, MeleroI. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol.37(5) , 508–516 (2010).
- Beatty GL , ChioreanEG, FishmanMP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331(6024) , 1612–1616 (2011).
- Dubrot J , MilheiroF, AlfaroC et al. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol. Immunother. 59(8) , 1223–1233 (2010).
- Mazzolini G , MurilloO, AtorrasagastiC et al. Immunotherapy and immunoescape in colorectal cancer. World J. Gastroenterol. 13(44) , 5822–5831 (2007).
- Malvicini M , IngolottiM, PiccioniF et al. Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12. Mol. Oncol. 5(3) , 242–255 (2011).
- Ko HJ , KimYJ, KimYS et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67(15) , 7477–7486 (2007).
- Vincent J , MignotG, ChalminF et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70(8) , 3052–3061 (2010).
- Michaud M , MartinsI, SukkurwalaAQ et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334(6062) , 1573–1577 (2011).
- Avella DM , LiG, SchellTD et al. Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology 55(1) , 141–152 (2012).
- Ma L , LuoL, QiaoH et al. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J. Hepatol. 46(1) , 98–106 (2007).
- Huang KW , WuHL, LinHL et al. Combining antiangiogenic therapy with immunotherapy exerts better therapeutical effects on large tumors in a woodchuck hepatoma model. Proc. Natl Acad. Sci. USA 107(33) , 14769–14774 (2010).
- Uno T , TakedaK, KojimaY et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 12(6) , 693–698 (2006).
- Melero I , Martinez-ForeroI, DubrotJ, SuarezN, PalazonA, ChenL. Palettes of vaccines and immunostimulatory monoclonal antibodies for combination. Clin. Cancer Res.15(5) , 1507–1509 (2009).
- Martinez-Forero I , OkadaH, TopalianSL, GajewskiTF, KormanAJ, MeleroI. Workshop on immunotherapy combinations society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011. J. Transl. Med.10(1) , 108 (2012).